Cytomed Therapeutics Announced That The Intellectual Property Corporation Of Malaysia Has Granted A Patent For Its Chimeric Antigen Receptor Gamma Delta T Cell Technology, Which Targets Solid And Hematological Tumors
Cytomed Therapeutics宣佈，馬來西亞知識產權公司已批准其針對實體腫瘤和血液學腫瘤的嵌合抗原受體伽瑪德爾塔T細胞技術的專利